VisentinR, Dalla ManC, KudvaYC, et al.: Circadian variability of insulin sensitivity: physiological input for in silico artificial pancreas. Diabetes Technol Ther, 2015; 17:1–7.
2.
RuanY, ThabitH, LeelarathnaL, et al.: Variability of insulin requirements over 12 weeks of closed-loop insulin delivery in adults with type 1 diabetes. Diabetes Care, 2016; 39:830–832.
3.
FrierBM: Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications. Nat Rev Endocrinol, 2014; 10:711–722.
4.
SartoreG, ChilelliNC, BurlinaS, LapollaA: Association between glucose variability as assessed by continuous glucose monitoring (CGM) and diabetic retinopathy in type 1 and type 2 diabetes. Acta Diabetol, 2013; 50:437–442.
5.
ThabitH, TauschmannM, AllenJM, et al.: Home use of an artificial beta cell in type 1 diabetes. N Engl J Med, 2015; 373:2129–2140.
6.
KropffJ, Del FaveroS, PlaceJ, et al.: 2 Month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial. Lancet Diabetes Endocrinol, 2015; 3:939–947.
7.
Eren-OrukluM, CinarA, QuinnL, SmithD: Adaptive control strategy for regulation of blood glucose levels in patients with type 1 diabetes. J Process Control, 2009; 19:1333–1346.
8.
DoyleFJ, HuyettLM, LeeJB, et al.: Closed-loop artificial pancreas systems: engineering the algorithms. Diabetes Care, 2014; 37:1191–1197.
9.
MessoriM, KropffJ, Del FaveroS, et al.: Individually adaptive artificial pancreas in subjects with type 1 diabetes: a one-month proof-of-concept trial in free-living conditions. Diabetes Technol Ther, 2017; 19:560–571.
10.
MagniL, ForgioneM, ToffaninC, et al.: Run-to-run tuning of model predictive control for type 1 diabetes subjects: in silico trial. J Diabetes Sci Technol, 2009; 3:1091–1098.
11.
RenardE, FarretA, KropffJ, et al.: Day-and-night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: results of a single-arm 1-month experience compared with a previously reported feasibility study of evening and night at home. Diabetes Care, 2016; 39:1151–1160.
12.
Keith-HynesP, GuerlainS, MizeB, et al.: DiAs user interface: a patient-centric interface for mobile artificial pancreas systems. J Diabetes Sci Technol, 2013; 7:1416–1426.
13.
ToffaninC, MessoriM, Di PalmaF, et al.: Artificial pancreas: model predictive control design from clinical experience. J Diabetes Sci Technol, 2013; 7:1470–1483.
14.
ToffaninC, VisentinR, MessoriM, et al.: Towards a run-to-run adaptive artificial pancreas: in silico results. IEEE Trans Biomed Eng, 2017Jan11; doi: 10.1109/TBME.2017.2652062.
15.
BallyL, ThabitH, KojzarH, et al.: Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study. Lancet Diabetes Endocrinol, 2017; 5:261–270.
16.
KovatchevB, ChengP, AndersonSM, et al.: Feasibility of long-term closed-loop control: a multicenter 6-month trial of 24/7 automated insulin delivery. Diabetes Technol Ther, 2017; 19:18–24.
17.
HaidarA, DuvalC, LegaultL, Rabasa-LhoretR: Pharmacokinetics of insulin aspart and glucagon in type 1 diabetes during closed-loop operation. J Diabetes Sci Technol, 2013; 7:1507–1512.
18.
BasuA, DubeS, VeettilS, et al.: Time lag of glucose from intravascular to interstitial compartment in type 1 diabetes. J Diabetes Sci Technol, 2015; 9:63–68.
19.
Russell-JonesD, BodeBW, De BlockC, et al.: Fast-acting insulin aspart improves glycemic control in basal-bolus treatment for type 1 diabetes: results of a 26-week multicenter, active-controlled, treat-to-target, randomized, parallel-group trial (onset 1). Diabetes Care, 2017; 40:943–950.
20.
El-KhatibFH, RussellSJ, MagyarKL, et al.: Autonomous and continuous adaptation of a bihormonal bionic pancreas in adults and adolescents with type 1 diabetes. J Clin Endocrinol Metab, 2014; 99:1701–1711.
21.
El-KhatibFH, BalliroC, HillardMA, et al.: Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial. Lancet, 2017; 389:369–380.
22.
VisentinR, Dalla ManC, KovatchevB, CobelliC: The university of Virginia/Padova type 1 diabetes simulator matches the glucose traces of a clinical trial. Diabetes Technol Ther, 2014; 16:428–434.
23.
WilinskaME, ChassinLJ, AceriniCL, et al.: Simulation environment to evaluate closed-loop insulin delivery systems in type 1 diabetes. J Diabetes Sci Technol, 2010; 4:132–144.
24.
KropffJ, DeJongJ, Del FaveroS, et al.: Psychological outcomes of evening and night closed-loop insulin delivery under free living conditions in people with Type 1 diabetes: a 2-month randomized crossover trial. Diabet Med, 2017; 34:262–271.
25.
BallyL, ThabitH, RuanY, et al.: Bolusing frequency and amount impacts glucose control during hybrid closed-loop. Diabet Med, 2017 Jul 29; doi: 10.1111/dme.13436.
26.
CameronFM, LyTT, BuckinghamBA, et al.: Closed-loop control without meal announcement in type 1 diabetes. Diabetes Technol Ther, 2017; 19:527–532.
27.
BrazeauAS, MircescuH, DesjardinsK, et al.: Carbohydrate counting accuracy and blood glucose variability in adults with type 1 diabetes. Diabetes Res Clin Pract, 2013; 99:19–23.
28.
OlinderAL, KernellA, SmideB: Missed bolus doses: devastating for metabolic control in CSII-treated adolescents with type 1 diabetes. Pediatr Diabetes, 2009; 10:142–148.
29.
BarnardKD, PinskerJE, OliverN, et al.: Future artificial pancreas technology for type 1 diabetes: what do users want?. Diabetes Technol Ther, 2015; 17:311–315.
